20.52 USD
+0.72 (+3.64%)
20.6097 USD
+0.09 (+0.44%)
We assign a fundamental rating of 4 out of 10 to TXG. TXG was compared to 57 industry peers in the Life Sciences Tools & Services industry. While TXG has a great health rating, there are worries on its profitability. TXG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TXG has reported negative net income.
In the past year TXG had a positive cash flow from operations.
In the past 5 years TXG always reported negative net income.
In the past 5 years TXG reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -7.43%, TXG is in line with its industry, outperforming 50.88% of the companies in the same industry.
TXG has a Return On Equity of -9.72%. This is comparable to the rest of the industry: TXG outperforms 54.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.43% | ||
| ROE | -9.72% | ||
| ROIC | N/A |
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TXG (68.90%) is better than 91.23% of its industry peers.
TXG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXG has more shares outstanding
TXG has more shares outstanding than it did 5 years ago.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.96 indicates that TXG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.96, TXG belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.96 |
ROIC/WACCN/A
WACC10.96%
2.3 Liquidity
TXG has a Current Ratio of 4.48. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.48, TXG is doing good in the industry, outperforming 73.68% of the companies in the same industry.
TXG has a Quick Ratio of 4.06. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
TXG has a better Quick ratio (4.06) than 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.48 | ||
| Quick Ratio | 4.06 |
3. Growth
3.1 Past
TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.25%, which is quite impressive.
The Revenue has been growing slightly by 1.92% in the past year.
The Revenue has been growing by 19.96% on average over the past years. This is quite good.
EPS 1Y (TTM)54.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%-1.75%
3.2 Future
The Earnings Per Share is expected to grow by 16.72% on average over the next years. This is quite good.
TXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.61% yearly.
EPS Next Y67.35%
EPS Next 2Y16.84%
EPS Next 3Y15.55%
EPS Next 5Y16.72%
Revenue Next Year4.41%
Revenue Next 2Y0.38%
Revenue Next 3Y2.98%
Revenue Next 5Y4.61%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TXG's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TXG is cheaper than 77.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.8 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TXG's earnings are expected to grow with 15.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.84%
EPS Next 3Y15.55%
5. Dividend
5.1 Amount
TXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
20.52
+0.72 (+3.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners107.99%
Inst Owner Change0.03%
Ins Owners1.6%
Ins Owner Change-0.79%
Market Cap2.60B
Revenue(TTM)641.81M
Net Income(TTM)-76.32M
Analysts70.91
Price Target17.54 (-14.52%)
Short Float %13.48%
Short Ratio5.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.5%
Min EPS beat(2)24.4%
Max EPS beat(2)174.61%
EPS beat(4)3
Avg EPS beat(4)47.23%
Min EPS beat(4)-34.43%
Max EPS beat(4)174.61%
EPS beat(8)6
Avg EPS beat(8)27.95%
EPS beat(12)7
Avg EPS beat(12)13.27%
EPS beat(16)8
Avg EPS beat(16)1.94%
Revenue beat(2)2
Avg Revenue beat(2)13.16%
Min Revenue beat(2)3.54%
Max Revenue beat(2)22.78%
Revenue beat(4)4
Avg Revenue beat(4)11.15%
Min Revenue beat(4)2.51%
Max Revenue beat(4)22.78%
Revenue beat(8)5
Avg Revenue beat(8)4.76%
Revenue beat(12)9
Avg Revenue beat(12)4.17%
Revenue beat(16)11
Avg Revenue beat(16)2.67%
PT rev (1m)4.03%
PT rev (3m)14.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.32%
EPS NY rev (1m)0%
EPS NY rev (3m)17.82%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)3.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.05 | ||
| P/FCF | 31.8 | ||
| P/OCF | 29.33 | ||
| P/B | 3.31 | ||
| P/tB | 3.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)0.65
FCFY3.14%
OCF(TTM)0.7
OCFY3.41%
SpS5.07
BVpS6.2
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.43% | ||
| ROE | -9.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.9% | ||
| FCFM | 12.72% |
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score5
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.81% | ||
| Cap/Sales | 1.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.48 | ||
| Quick Ratio | 4.06 | ||
| Altman-Z | 4.96 |
F-Score5
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)231.92%
Cap/Depr(5y)289.86%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y67.35%
EPS Next 2Y16.84%
EPS Next 3Y15.55%
EPS Next 5Y16.72%
Revenue 1Y (TTM)1.92%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%-1.75%
Revenue Next Year4.41%
Revenue Next 2Y0.38%
Revenue Next 3Y2.98%
Revenue Next 5Y4.61%
EBIT growth 1Y21.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.86%
EBIT Next 3Y16.93%
EBIT Next 5Y15.76%
FCF growth 1Y172.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y424.98%
OCF growth 3YN/A
OCF growth 5Y-28.08%
10X GENOMICS INC-CLASS A / TXG FAQ
Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?
ChartMill assigns a fundamental rating of 4 / 10 to TXG.
What is the valuation status of 10X GENOMICS INC-CLASS A (TXG) stock?
ChartMill assigns a valuation rating of 1 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.
Can you provide the profitability details for 10X GENOMICS INC-CLASS A?
10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.
Can you provide the financial health for TXG stock?
The financial health rating of 10X GENOMICS INC-CLASS A (TXG) is 8 / 10.